Walgreen

Walgreens Boots Alliance, Inc. settled for $100 million over claims of misleading generic drug pricing. UBS raised its price target from $9 to $10, while Morgan Stanley cut its target from $9 to $7.

Walgreens was one of the worst S&P 500 performers this year, raising concerns about possible tax-loss selling. CVS Health also faces challenges, suggesting it may encounter similar selling pressures.